The Food and Drug Administration (FDA) has approved Trikafta (elexacaftor/tezacaftor/ivacaftor; Vertex) for the treatment of patients aged 12 years and older with cystic fibrosis (CF) who have ≥1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Trikafta is a fixed-dose combination containing elexacaftor 100mg, tezacaftor 50mg, and ivacaftor 75mg that is co-packaged…
In an early-release Oct. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, the CDC presents interim guidance to help clinicians assess, evaluate, manage, and follow patients with electronic cigarette, or vaping, product use-associated lung injury.
A Clinical Update review published in JAMA detailed current research surrounding the efficacy and safety of obesity treatment for adolescents, including behavioral interventions, pharmacotherapy, and bariatric surgery.
Free distribution of essential medicines was shown to improve treatment adherence. Bettering access to essential medicines can improve quality of care and move toward achieving univer-sal health coverage.
The benefits of early diagnosis of chronic kidney disease (CKD) are significant, as patients in whom CKD is diagnosed in the early stages have the chance to make lifestyle changes, learn how to manage their disease, and extend their lives while avoiding or postponing the need for dialysis or transplant.